↓ Skip to main content

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada

Overview of attention for article published in BMC Cancer, October 2021
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
2 X users

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
Published in
BMC Cancer, October 2021
DOI 10.1186/s12885-021-08746-z
Pubmed ID
Authors

Jaclyn M. Beca, Shaun Walsh, Kaiwan Raza, Stacey Hubay, Andrew Robinson, Elena Mow, James Keech, Kelvin K. W. Chan

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 14%
Student > Bachelor 1 7%
Unspecified 1 7%
Unknown 10 71%
Readers by discipline Count As %
Unspecified 1 7%
Biochemistry, Genetics and Molecular Biology 1 7%
Computer Science 1 7%
Medicine and Dentistry 1 7%
Unknown 10 71%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2021.
All research outputs
#15,155,790
of 23,310,485 outputs
Outputs from BMC Cancer
#3,757
of 8,441 outputs
Outputs of similar age
#233,071
of 439,690 outputs
Outputs of similar age from BMC Cancer
#70
of 212 outputs
Altmetric has tracked 23,310,485 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,441 research outputs from this source. They receive a mean Attention Score of 4.4. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,690 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 212 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.